---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-25-000044"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:54:43.210671+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acumen 2024 net loss $102.3M; cash $231.5M; ALTITUDE-AD enrollment complete

## Summary
- Net loss $102.3M vs $52.4M in 2023; R&D spend $93.8M (up 122%) driven by ALTITUDE-AD trial.
- Cash, equivalents and marketable securities $231.5M, down from $306.1M; runway into H1 2027.
- Phase 2 ALTITUDE-AD enrolled 542 early AD patients; topline results expected late 2026.
- Phase 1 subcutaneous sabirnetug showed mild injection-site reactions; supports further SC development.
- JPAD published Phase 1 INTERCEPT-AD results; sabirnetug well-tolerated with dose-dependent target engagement.

## SEC filing metadata
- accession: 0001576885-25-000044
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688525000044/0001576885-25-000044-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688525000044/abos-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-25-000044
- JSON: https://secwatch.observer/filing/0001576885-25-000044.json
- Plain text: https://secwatch.observer/filing/0001576885-25-000044.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.